Established among biotech practitioners as the market leading event, C5 s Biotech Patenting Conference is the one place biotech patent practitioners come to learn and discuss the most recent and vital changes facing the industry today.
Intellectual property is central to the biotechnology industry. High R&D costs and the lengthy product testing times that are required before a biotech product can enter the market make it particularly important for companies to be able to reap the full benefit and duration afforded by patent protection before generic producers enter the market.
At the same time, maximising protection and value of your company s biotechnology has become more and more complex as patent law continually evolves to keep pace with the rapid developments in biotechnology innovation. Ground-breaking case law decisions, legislative developments and evolving standards of the EPO and national patent offices mean that the rules of the game for qualifying for and defining the scope of your biotechnology patent are changing constantly and rapidly.
In this fast changing high stakes industry it is imperative to have an up-to-the-minute in-depth understanding of the decisions of the European and US courts and the very latest policies and practice of the EPO and USPTO.
In response to this, C5 has specifically designed its Biotech Patenting conference to provide you with a sophisticated and comprehensive understanding of the issues you face today.
The
18th C5 Forum on Biotech Patenting brings together a panel of experts comprising regulators, in-house counsel and their advisors, to provide you with an essential briefing and update on the state of biotech patenting today. By attending, you will:
- Follow a lively debate on the latest strategies for adapting your patent practice to EPO rule changes
- Hear directly from the EPO on patentability, their latest requirements and key policy changes
- Find out about disclosure requirements for gene patents: from T 1329/04 to Eli Lily vs HGS what is patentable?
- Identify what the Enlarged Board s Decision on Second Medical Use Claims means for your claims drafting
- Maximise your patent protection with a critical review of recent developments and decisions on the availability of SPCs
- Improve your claims drafting to meet heightened patentability requirements for antibodies
- Master the ethical minefield: defining embryonic stem cells within Europe s borders
